hexarelin (EN)

Draft · focused evidence review · clinical sign-off pending · not publicly published

Does stronger hormone release mean a better treatment?

Hexarelin, also known as examorelin, is a synthetic growth-hormone secretagogue. Interest in its endocrine and cardiovascular actions has produced research questions, not a general prescription for recovery or longevity.

Potency at a receptor is not a ranking of clinical usefulness.

Evidence: Small human endocrine and cardiac studies; preclinical cardiovascular experiments

Jurisdiction: Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.

A relative of other GH-releasing peptides

Hexarelin acts at the ghrelin receptor and can stimulate pituitary growth-hormone release. It is structurally related to GHRP-6. Comparisons of hormone responses are useful pharmacology, but they cannot tell us which compound would improve a patient’s symptoms or daily functioning.

Why the heart findings are interesting

In a 1999 rat model, hexarelin reduced several measures of damage after interrupted blood supply and reperfusion. That gives the cardiac-protection hypothesis a concrete experimental basis. A different study linked hexarelin to CD36 and increased coronary perfusion pressure in isolated hearts. Cardiovascular activity can therefore have different meanings in different models; these results do not establish fewer heart attacks or longer survival in people. [3] [1]

A short human study adds another clue

A controlled study in 24 men undergoing coronary bypass surgery found a short-lived improvement in cardiac pumping measurements after hexarelin, including ejection fraction and cardiac output. Mean arterial pressure also increased. This human physiological signal deserves mention, but the surgical setting and brief measurements do not establish fewer cardiovascular events, longer survival or a benefit for healthy users. [4]

The hormone response changed over time

In 12 healthy older adults studied over 16 weeks, the GH response to hexarelin diminished during treatment and recovered after treatment stopped. The investigators described partial, reversible desensitisation. This makes adaptation a measured finding, rather than speculation. It does not establish a cycling schedule or show that maintaining a larger GH response improves health. [2]

Hormonal and cardiovascular safety questions

Growth-hormone stimulation can interact with glucose regulation, fluid balance and other endocrine responses. Cardiovascular activity also deserves direct safety evaluation rather than being labelled protective by default. The evidence can guide further research. It does not show that a more potent secretagogue offers greater benefits or fewer risks.

Encyclopedia / Lexikon

What / Einordnung

Hexarelin, also called examorelin, is a synthetic growth-hormone secretagogue related to GHRP-6. It has also been investigated in cardiovascular research.

Mechanism / Mechanismus

It stimulates GH release through the ghrelin receptor. Laboratory cardiovascular research has explored additional interactions, including the CD36 protein.

Why the heart findings are interesting

In a 1999 rat model, hexarelin reduced several measures of damage after interrupted blood supply and reperfusion. That gives the cardiac-protection hypothesis a concrete experimental basis. A different study linked hexarelin to CD36 and increased coronary perfusion pressure in isolated hearts. Cardiovascular activity can therefore have different meanings in different models; these results do not establish fewer heart attacks or longer survival in people. [3] [1]

Preclinical cardiac experiments; clinical cardiovascular outcomes unresolved.

The hormone response changed over time

In 12 healthy older adults studied over 16 weeks, the GH response to hexarelin diminished during treatment and recovered after treatment stopped. The investigators described partial, reversible desensitisation. This makes adaptation a measured finding, rather than speculation. It does not establish a cycling schedule or show that maintaining a larger GH response improves health. [2]

Small repeated-exposure human endocrine study.

A short human study adds another clue

A controlled study in 24 men undergoing coronary bypass surgery found a short-lived improvement in cardiac pumping measurements after hexarelin, including ejection fraction and cardiac output. Mean arterial pressure also increased. This human physiological signal deserves mention, but the surgical setting and brief measurements do not establish fewer cardiovascular events, longer survival or a benefit for healthy users. [4]

Small controlled acute human study; surrogate physiological measurements.

Safety / Sicherheit

Glucose regulation, fluid balance and other hormonal responses require attention. Cardiovascular activity should not be assumed protective without direct clinical assessment.

FAQ

Does stronger GH release make it a better treatment?

Not by itself. Potency at a hormonal endpoint does not establish a better balance of functional benefit and adverse effects.

Is its heart-protection claim established in people?

Human work shows short-term changes in cardiac pumping measurements, alongside preclinical protective findings. These studies do not establish fewer cardiovascular events or longer survival. [1] [3] [4]

Sources / Quellen

[1] Bodart et al. (2002): CD36 mediates cardiovascular action of growth hormone-releasing peptides — Primary research. PubMed abstract checked; full paper not reviewed; checked 2026-10-29

[2] Rahim & Shalet (1998): Does desensitization to hexarelin occur? — Primary research. PubMed abstract checked; full paper not reviewed; checked 2026-10-29

[3] 1999: Hexarelin and ischemia-reperfusion injury in rat hearts — Primary preclinical research. Indexed primary-paper abstract checked; checked 2026-10-29

[4] Broglio et al. (2002): Acute hexarelin and cardiac performance during bypass surgery — Small controlled human physiological study. PubMed abstract checked 2026-10-29; full methods not reviewed